



Certificate on translated version of material subsidiary audited financial statements

Date: 15-December-2023

To,

**The Board of Directors
Emcure Pharmaceuticals Limited**
Plot No. P-1 & P-2, IT-BT Park
Phase-II, M.I.D.C.
Hinjawadi, Pune – 411 057
Maharashtra, India

Emcure Pharma UK Limited
220 Butterfield
Great Marlings
Luton
LU2 8DK
United Kingdom

Re: Proposed initial public offering of equity shares (the “Equity Shares”) of Emcure Pharmaceuticals Limited (the “Company” and such offering, the “Offer”)

Dear Sirs,

We have verified the translated version of the audited standalone financial statements of **Emcure Pharma UK Limited**. (the “Company”) for the years ended March 31, 2023, March 31, 2022 and March 31, 2021 (“Financial Years”). These financial statements have been translated by the Company in Indian Rupee in accordance with Ind AS 21, ‘The Effect of Changes in Foreign Currency Rates’. The work carried out by us is in accordance with the Standard on Related Services (SRS) 4400, “Engagements to Perform Agreed-upon Procedures regarding Financial Information” issued by the Institute of Chartered Accountants of India.

As required under Schedule VI Part A item no.(11)(I)(A)(ii)(b) of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”), we have verified the translated financial information contained in the Annexure attached to this certificate which is proposed to be uploaded on the website of **Emcure Pharmaceuticals Limited** in connection with its proposed initial public offering of equity shares of Rs. 10/- each (the “Offer”).

We did not audit the standalone financial statements of **Emcure Pharma UK Limited**. These financial statements have been audited by other audit firms, whose reports have been furnished to us by the Company.

These translated financials should not in any way be construed as a reissuance or re-dating of any of the previous audit reports, nor should these be construed as a new opinion on any of the audited standalone financial statements referred to herein.

These translated financials are intended solely for use of the management for uploading on website of **Emcure Pharmaceuticals Limited** in connection with its proposed initial public offering of equity shares of Rs. 10/- each.



Based on our examination, we confirm that the information in this certificate is true, fair, correct, accurate and there is no untrue statement or omission which would render the contents of this certificate misleading in its form or context.


Restriction on use

This certificate has been provided by M/s. R.B. Sharma and Co., Chartered Accountants, at the request of Emcure Pharmaceuticals Limited and solely for the information of **Kotak Mahindra Capital Company Limited, Axis Capital Limited, Jefferies India Private Limited, J.P. Morgan India Private Limited** and any other book running lead managers appointed by Emcure Pharmaceuticals Limited (collectively referred to as the "Book Running Lead Managers" or the "BRLMs") to assist them in conducting their due-diligence and documenting their investigations of the affairs of Emcure Pharmaceuticals Limited in connection with the proposed Offer. This certificate may be relied on by the BRLMs, their affiliates and legal counsel in relation to the Offer.

This certificate is not intended for general circulation or publication and is not to be reproduced or used for any other purpose without our prior consent in writing, other than for the purpose stated above. We, however, hereby give consent for inclusion of our name and this information (in full or in part) in the Draft Red Herring Prospectus, Updated Draft Red Herring Prospectus, Red Herring Prospectus and Prospectus proposed to be filed by Emcure Pharmaceuticals Limited with the Securities and Exchange Board of India ("SEBI"), the stock exchanges where the Equity Shares of Emcure Pharmaceuticals Limited are proposed to be listed (the "Stock Exchanges") and the Registrar of Companies, Maharashtra at Pune ("RoC") and any other material used in connection with the Offer and submission of this certificate to SEBI, Stock Exchanges, or RoC in connection with the proposed Offer, as the case may be. Additionally, we hereby give our consent for the submission of this certificate to any other regulatory authority as may be required under applicable law in connection with the proposed Offer, as the case may be.

Yours Sincerely,

For
M/s R.B. Sharma and Co.
Chartered Accountants
ICAI Firm Registration No:109971W


Madhavan N Iyengar
Partner
Membership No. 044366
UDIN: 23044366BGUUAH3870



CC:

Khaitan & Co
10th & 13th Floors, Tower 1C
One World Centre
841, Senapati Bapat Marg
Mumbai 400 013
Maharashtra, India

Shardul Amarchand Mangaldas & Co
Express Towers
24th Floor, Nariman Point
Mumbai 400 021
Maharashtra, India

Sidley Austin LLP
Level 31
Six Battery Road
Singapore 049909

EMCURE PHARMA UK LTD
Translated Version Of Audited Balance Sheet

Balance Sheet	Note	GBP			INR (million)		
		31.03.2023	31.03.2022	31.03.2021	31.03.2023	31.03.2022	31.03.2021
Fixed assets							
Tangible assets	11	1	1	1	-	-	-
Investments	12	40,288,196	39,048,589	38,522,880	3,914.60	3,788.93	3,734.91
		40,288,197	39,048,590	38,522,881	3,914.60	3,788.93	3,734.91
Assets							
Current assets:							
Debtors: amounts falling due within one year	13	10,848,567	8,879,487	7,245,698	1,099.56	884.13	730.46
Cash at bank and in hand	14	601,395	460,424	404,719	60.96	45.84	40.80
		11,449,962	9,339,911	7,650,417	1,160.52	929.97	771.26
Creditors: amounts falling due within one year	15	(5,154,099)	(3,626,995)	(3,324,765)	(522.40)	(361.13)	(335.18)
Net current assets		6,295,863	5,712,916	4,325,652	638.12	568.84	436.08
Total assets less current liabilities		45,442,296	42,675,585	41,847,646	4,437.00	4,249.17	4,218.80
Creditors: amounts falling due after more than one year	16	(9,901,340)	(8,115,000)	(6,000,000)	(1,003.56)	(808.00)	(604.88)
Net current (liabilities)/assets		(3,605,477)	(2,402,084)	(1,674,348)	(365.44)	(239.16)	(168.80)
Net assets		36,682,720	36,646,506	36,848,533	3,549.16	3,549.77	3,566.11
Capital and reserves							
Called up share capital	17	32,765,000	32,765,000	32,765,000	3,110.06	3,110.06	3,110.06
Foreign currency translation reserve					76.51	80.64	76.41
Profit and loss account	18	3,917,720	3,881,506	4,083,533	362.59	359.07	379.64
		36,682,720	36,646,506	36,848,533	3,549.16	3,549.77	3,566.11

The notes form part of these financial statements.

M/s. R.B. Sharma and Co.
Chartered Accountants
ICAI Firm Registration No: 109971W



Madhavan N Iyengar
Partner
Membership No. 044366
Date: 15 December 2023
Place: Pune



For and on behalf of EMCURE PHARMA UK LTD



Tajuddin Shaikh
Authorised Signatory

Date: 15 December 2023
Place: Pune



EMCURE PHARMA UK LTD

Translated Version Of Audited Statement Of Comprehensive Income

	Note	GBP			INR (million)		
		31.03.2023	31.03.2022	31.03.2021	31.03.2023	31.03.2022	31.03.2021
Turnover	4	1,052,091	692,926	303,582	101.88	70.54	29.47
Cost of sales		(745,020)	(639,721)	(242,575)	(72.14)	(65.12)	(23.55)
Gross profit		307,071	53,205	61,007	29.74	5.42	5.92
Administrative expenses		(13,327)	(220,348)	(248,223)	(1.28)	(22.44)	(24.08)
Other operating income	5	-	-	9,943	-	-	0.97
Operating profit/Loss	5	293,744	(167,143)	(177,273)	28.46	(17.02)	(17.19)
Interest receivable and similar income	8	229,480	191,331	357,584	22.22	19.48	34.71
Interest payable and similar expenses	9	(462,608)	(273,603)	(257,720)	(44.80)	(27.85)	(25.02)
Profit/(loss) before tax		60,616	(249,415)	(77,409)	5.88	(25.39)	(7.50)
Tax on profit/(loss)	10	(24,402)	47,388	14,708	(2.36)	4.82	1.43
Profit/(Loss) for the financial year		36,214	(202,027)	(62,701)	3.52	(20.57)	(6.07)

There were no recognised gains and losses for 2023, 2022 or 2021 other than those included in the statement of comprehensive income.

There was no other comprehensive income for 2023 (2022:€NIL, 2021:€NIL).

The notes form part of these financial statements.

M/s. R.B. Sharma and Co.
Chartered Accountants
ICAI Firm Registration No: 109971W



Madhavan N Iyengar
Partner
Membership No. 044366
Date: 15 December 2023
Place: Pune



For and on behalf of EMCURE PHARMA UK LTD



Tajuddin Shaikh
Authorised Signatory

Date: 15 December 2023
Place: Pune



EMCURE PHARMA UK LTD
Translated Version of Audited Statement Of Changes In Equity

Share capital	GBP		
	31.03.2023	31.03.2022	31.03.2021
Opening	32,765,000	32,765,000	32,765,000
Change during the year	-	-	-
Closing	32,765,000	32,765,000	32,765,000

31.03.2023	INR (million)	
	31.03.2022	31.03.2021
3,110.06	3,110.06	3,110.06
-	-	-
3,110.06	3,110.06	3,110.06

Profit and loss account	GBP		
	31.03.2023	31.03.2022	31.03.2021
Opening	3,881,506	4,083,533	4,146,234
Profit/(Loss) for the financial year	36,214	(202,027)	(62,701)
Closing	3,917,720	3,881,506	4,083,533

31.03.2023	INR (million)	
	31.03.2022	31.03.2021
359.07	379.64	385.71
3.52	(20.57)	(6.07)
362.59	359.07	379.64

Foreign currency translation reserve	GBP		
	31.03.2023	31.03.2022	31.03.2021
FCTR on Share Capital			
FCTR on Investments			
FCTR on Profit and loss account			
Total			

31.03.2023	INR (million)	
	31.03.2022	31.03.2021
210.87	152.33	193.08
(168.86)	(99.10)	(148.70)
34.50	27.41	32.03
76.51	80.64	76.41

The notes form part of these financial statements.

M/s. R.B. Sharma and Co.
Chartered Accountants
ICAI Firm Registration No: 109971W

Madhavan N Iyengar

Madhavan N Iyengar
Partner
Membership No. 044366
Date: 15 December 2023
Place: Pune



For and on behalf of EMCURE PHARMA UK LTD

Tajuddin Shalkh

Tajuddin Shalkh
Authorised Signatory

Date: 15 December 2023
Place: Pune



EMCURE PHARMA UK LTD
Translated Version of Notes to Financial Statements

1 General information

Emcure Pharma UK Limited is a limited liability company incorporated in England and Wales. It is a 100% owned subsidiary undertaking of Emcure Pharmaceuticals Limited, a company registered in India.

The Company's functional and presentational currency is British pound sterling.

The registered office and principal place of activity is 220 Butterfield, Great Marlings, Luton, LU2 8DL.

2 Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies (see note 3).

The following principal accounting policies have been applied:

2.2 Financial reporting standard 102 - reduced disclosure exemptions

The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

- the requirements of Section 7 Statement of Cash Flows;
- the requirements of Section 3 Financial Statement Presentation paragraph 3.17(d);
- the requirements of Section 11 Financial Instruments paragraphs 11.42, 11.44 to 11.45, 11.47, 11.48(a)(iii), 11.48(a)(iv), 11.48(b) and 11.48(c);
- the requirements of Section 12 Other Financial Instruments paragraphs 12.26 to 12.27, 12.29(a), 12.29(b) and 12.29A;
- the requirements of Section 33 Related Party Disclosures paragraph 33.7.

This information is included in the consolidated financial statements of Emcure Pharmaceuticals Limited as at 31 March 2023, As at 31 March 2022 and as at 31 March 2021 which are filed along with this entity's financial statements each year, and these financial statements may be obtained from Companies House.

2.3 Exemption from preparing consolidated financial statements

The Company is a parent company that is also a subsidiary included in the consolidated financial statements of a larger group by a parent undertaking established under the law of a state other than the United Kingdom and is therefore exempt from the requirement to prepare consolidated financial statements under section 401 of the Companies Act 2006.

2.4 Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses are presented in the profit or loss within 'administrative expenses'.

2.5 Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:

- the Company has transferred the significant risks and rewards of ownership to the buyer;
- the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- the amount of revenue can be measured reliably;
- it is probable that the Company will receive the consideration due under the transaction; and
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

2.6 Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

2.7 Interest Income

Interest income is recognised in profit or loss using the effective interest method.



2.8 Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

2.9 Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Balance Sheet date, except that:

- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

2.10 Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Computer equipment and fixtures & fittings	10 - 33% per annum
--	--------------------

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

2.11 Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

2.12 Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.13 Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.14 Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

2.15 Financial Instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

Financial assets and liabilities are offset and the net amount reported in the Balance Sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

3 Judgments in applying accounting policies and key sources of estimation uncertainty

The Company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are addressed below:

Impairment of investment

The company has made investments by way of share capital in its 100% wholly owned subsidiaries. Management annually reviews the sales forecasts and profitability of all the subsidiaries so as to assess whether any impairment needs to be recognised in respect of any of the subsidiaries.



4 Turnover

The whole of the turnover is attributable to the sale of pharmaceutical products.

Analysis of turnover by country of destination:

	GBP			INR (million)		
	2023	2022	2021	2023	2022	2021
Europe	1,052,091	692,926	303,582	101.88	70.54	29.47
	1,052,091	692,926	303,582	101.88	70.54	29.47

5 Operating profit/(loss)

The operating profit/(loss) is stated after charging:

	GBP			INR (million)		
	2023	2022	2021	2023	2022	2021
Miscellaneous income	-	-	9,943	-	-	0.97
Exchange differences	(315,628)	184,211	190,177	(30.56)	18.75	18.46
Other operating lease rentals	13,217	11,960	11,100	1.28	1.22	1.08
	(302,411)	196,171	211,220	(29.28)	19.97	20.51

6 Auditor's remuneration

	GBP			INR (million)		
	2023	2022	2021	2023	2022	2021
Fees payable to the Company's auditor for the audit of the Company's annual financial statements	13,100	10,750	10,000	1.27	1.09	0.97

7 Employees

The average monthly number of employees, including the Directors, during the year was as follows:

	2023	2022	2021
	No.	No.	No.
Administration	5	5	3

8 Interest receivable

	GBP			INR (million)		
	2023	2022	2021	2023	2022	2021
Non- bank loan interest receivable	229,480	191,331	357,584	22.22	19.48	34.71

9 Interest payable and expenses

	GBP			INR (million)		
	2023	2022	2021	2023	2022	2021
Non-bank loan interest payable	462,608	273,603	257,720	44.80	27.85	25.02

10 Taxation

Corporation tax

	GBP			INR (million)		
	2023	2022	2021	2023	2022	2021
Current tax/ (Losses group relieved)	24,402	(47,388)	(14,708)	2.36	(4.82)	(1.43)
Total current tax	24,402	(47,388)	(14,708)	2.36	(4.82)	(1.43)
Deferred tax	-	-	-	-	-	-
Total deferred tax	-	-	-	-	-	-

Factors affecting tax charge for the year

The tax assessed for the year is higher than the standard rate of corporation tax in the UK of 19%. The differences are explained below:

	GBP			INR (million)		
	2023	2022	2021	2023	2022	2021
Profit/(loss) on ordinary activities before tax	60,616	(249,415)	(77,409)	5.87	(25.39)	(7.51)
Profit/(loss) on ordinary activities multiplied by standard rate of corporation tax in the UK of 19%	11,517	(47,388)	(14,708)	1.12	(4.82)	(1.43)
Effects of:						
Expenses not deductible for tax purposes, other than goodwill amortisation and impairment	12,885	-	-	1.24	-	-
Total tax charge for the year	24,402	(47,388)	(14,708)	2.36	(4.82)	(1.43)

Factors that may affect future tax charges

Corporation tax rates will increase from 1 April 2023. Companies with profits of £50,000 or less will be taxed at 19%. Where taxable profits are between £50,000 and £250,000, 25% rate will apply but with a marginal relief applying as profits increase.



11 Tangible fixed assets

	GBP			INR (million)		
	2023	2022	2021	2023	2022	2021
Cost						
At 1 April	32,816	32,816	33,780	3.08	3.08	3.17
Disposals	-	-	(964)	-	-	(0.09)
At 31 March	32,816	32,816	32,816	3.08	3.08	3.08
Depreciation						
At 1 April	32,815	32,815	33,779	3.08	3.08	3.17
Disposals	-	-	(964)	-	-	(0.09)
At 31 March	32,815	32,815	32,815	3.08	3.08	3.08
Net Book value						
At 31 March	1	1	1	-	-	-

12 Fixed asset investments

	GBP			INR (million)		
	2023	2022	2021	2023	2022	2021
Cost						
At 1 April	39,048,589	38,522,880	15,491,588	3,788.93	3,734.91	1,513.77
Additions	1,361,761	525,709	23,031,292	137.57	54.02	2,221.14
Deletions	(15,249)	-	-	(1.55)	-	-
At 31 March	40,395,101	39,048,589	38,522,880	3,924.95	3,788.93	3,734.91
Impairment						
At 1 April	-	-	-	-	-	-
Charge for the period	106,905	-	-	10.35	-	-
At 31 March	106,905	-	-	10.35	-	-
Net Book value						
At 31 March	40,288,196	39,048,589	38,522,880	3,914.60	3,788.93	3,734.91

Subsidiary undertakings

The following were 100% subsidiary undertakings of the Company:

Name	Registered office	Class of shares
Tillomed Laboratories Limited	220 Butterfield, Great Marlings, Luton, England, LU2 8DL	£ 1 "A" ordinary £ 1 "B" ordinary
Tillomed Pharma GmbH	Manhagener Allee 36, 22926 Ahrensburg, Germany	€1 ordinary
Laboratorios Tillomed Spain SLU	Calle de Cardenal Marcelo Spinola 8, planta 1, puerta F, 28016 Madrid, Spain	€1 ordinary
Tillomed Italia S.R.L	Viale Giulio Richard, 1 – Torre A, 20143 Milan, Italy	€1 ordinary
Tillomed France SAS	34 rue Jean Mermoz 78600 Malsons Laffitte	€10 ordinary
Tillomed d.o.o	Masarykova Ulica 21, PIN 81468037481 Zagreb	€1 ordinary
Emcure Pharma Peru SAC	AV. Circunvalacion del club golf los incas 170 1803 Edificio torre more urb club golg los incas1 033 Santiago de surco lima Peru 0362	€1 ordinary

The principal business activity of all the subsidiaries is trading in pharmaceutical products.

13 Debtors

	GBP			INR (million)		
	2023	2022	2021	2023	2022	2021
Trade debtors	653,582	918,654	881,658	66.24	91.47	88.88
Amounts owed by group undertakings	10,168,185	7,953,932	6,326,230	1,030.61	791.97	637.77
Other debtors	25,782	5,910	36,893	2.61	0.59	3.72
Prepayments and accrued income	1,018	991	917	0.10	0.10	0.09
	10,848,567	8,879,487	7,245,698	1,099.56	884.13	730.46

Amounts owed by group undertakings are unsecured, has no fixed rate of repayment and are repayable on demand.

14 Cash and cash equivalents

	GBP			INR (million)		
	2023	2022	2021	2023	2022	2021
Cash at bank and in hand	601,395	460,424	404,719	60.96	45.84	40.80



15 Creditors: Amounts falling due within one year

	GBP			INR (million)		
	2023	2022	2021	2023	2022	2021
Trade creditors	78,274	70,331	75,924	7.93	7.00	7.65
Amounts owed to group undertakings	5,039,243	3,481,272	3,197,753	510.76	346.63	322.38
Corporation tax	24,402	-	-	2.47	-	-
Other creditors	180	62,392	51,088	0.02	6.21	5.15
Accruals	12,000	13,000	-	1.22	1.29	-
	5,154,099	3,626,995	3,324,765	522.40	361.13	335.18

Amounts owed to group undertakings are interest free, unsecured and repayable on demand.

16 Creditors: Amounts falling due after more than one year

	GBP			INR (million)		
	2023	2022	2021	2023	2022	2021
Amounts owed to group undertakings	9,901,340	8,115,000	6,000,000	1,003.56	808.00	604.88
	9,901,340	8,115,000	6,000,000	1,003.56	808.00	604.88

Amounts owed to group undertakings represents the loan from Tillomed Laboratories Limited and the average interest rate for the year 5.12%. The maturity date of the loan is 11 September 2026.

17 Share capital

	GBP			INR (million)		
	2023	2022	2021	2023	2022	2021
Allotted, called up and fully paid						
Ordinary shares of ₹1.00 each	32,765,000	32,765,000	32,765,000	3,110.06	3,110.06	3,110.06

18 Reserves

Profit and loss account

Profit and loss account - Includes all current and previous period retained profits and losses.

19 Commitments under operating leases

the Company had future minimum lease payments due under non cancellable operating leases for each of the following periods:

	GBP			INR (million)		
	2023	2022	2021	2023	2022	2021
Not later than 1 year	-	-	2,040	-	-	0.21
	-	-	2,040	-	-	0.21

20 Controlling party

The immediate and ultimate parent undertaking and controlling party is Emcure Pharmaceuticals Limited, a company incorporated in India.

Emcure Pharmaceuticals Limited is the parent undertaking of the largest and smallest group of undertakings to consolidate these financial statements. The consolidated financial statements of Emcure Pharmaceuticals Limited are filed along with this entity's financial statements each year, and these financial statements may be obtained from Companies House online.



DETAILED PROFIT AND LOSS ACCOUNT

	GBP			INR (million)		
	2023	2022	2021	2023	2022	2021
Turnover	1,052,091	692,926	303,582	101.88	70.54	29.47
Cost of sales	(745,020)	(639,721)	(242,575)	(72.14)	(65.12)	(23.55)
Gross profit	307,071	53,205	61,007	29.74	5.42	5.92
Gross profit %	29.2%	7.7%	20.1%	29.2%	7.7%	20.1%
Other operating income	-	-	9,943	-	-	0.97
	307,071	53,205	70,950	29.74	5.42	6.89
Less: overheads						
Administration expenses	(13,327)	(220,348)	(248,223)	(1.28)	(22.44)	(24.08)
Operating profit/ (loss)	293,744	(167,143)	(177,273)	28.46	(17.02)	(17.19)
Interest receivable	229,480	191,331	357,584	22.22	19.48	34.71
Interest payable	(462,608)	(273,603)	(257,720)	(44.80)	(27.85)	(25.02)
Tax on profit/(loss) on ordinary activities	(24,402)	47,388	14,708	(2.36)	4.82	1.43
Profit/ (Loss) for the year	36,214	(202,027)	(62,701)	3.52	(20.57)	(6.07)
Turnover						
	2023	2022	2021	2023	2022	2021
Sales	1,052,091	692,926	303,582	101.88	70.54	29.47
	1,052,091	692,926	303,582	101.88	70.54	29.47
Cost of sales						
	2023	2022	2021	2023	2022	2021
Purchases	745,020	639,721	242,575	72.14	65.12	23.55
	745,020	639,721	242,575	72.14	65.12	23.55
Other operating income						
	2023	2022	2021	2023	2022	2021
Other income	-	-	9,943	-	-	0.97
	-	-	9,943	-	-	0.97
Administration expenses						
	2023	2022	2021	2023	2022	2021
Consultancy	6,218	2,023	2,457	0.60	0.21	0.24
General office expenses	-	152	542	-	0.02	0.05
Legal and professional	-	-	3,726	-	-	0.36
Auditors' remuneration	10,288	13,600	24,350	1.00	1.38	2.36
Bank charges	464	671	10,428	0.04	0.07	1.01
Difference on foreign exchange	(315,628)	184,211	190,177	(30.56)	18.75	18.46
Bad debts	224,834	-	-	21.77	-	-
Rent	13,217	11,960	11,100	1.28	1.22	1.08
Rates	4,961	2,420	2,420	0.48	0.25	0.23
Insurances	400	300	-	0.04	0.03	-
Reversal of prior year ESOP expense	(39,088)	-	-	(3.79)	-	-
Impairment of investment	106,905	-	-	10.35	-	-
Product registration	-	4,255	1,799	-	0.43	0.17
License fees	756	756	1,224	0.07	0.08	0.12
	13,327	220,348	248,223	1.28	22.44	24.08



EMCURE PHARMA UK LTD
Translated Version of Notes to Financial Statements

Interest receivable	GBP			INR (million)		
	2023	2022	2021	2023	2022	2021
Non-bank interest receivable	229,480	191,331	357,584	22.22	19.48	34.71

Interest payable	GBP			INR (million)		
	2023	2022	2021	2023	2022	2021
Non-bank loan interest payable	462,608	273,603	257,720	44.80	27.85	25.02

- 21 **Foreign Currency translation**
Monetary Assets and Liabilities of the Company have been translated to the Indian currency using exchange rates prevailing on the balance sheet date. Statement of profit and loss has been translated using average exchange rates. Share capital and Long term investments are translated into Indian currency at exchange rate prevalent on the date of transaction. Translation adjustments have been reported as foreign currency translation reserve in the other comprehensive income which is presented within equity.

M/s. R.B. Sharma and Co.
Chartered Accountants
ICAI Firm Registration No: 109971W

Madhavan N Iyengar

Madhavan N Iyengar
Partner
Membership No. 044366
Date: 15 December 2023
Place: Pune



For and on behalf of EMCURE PHARMA UK LTD

Tajuddin Shaikh

Tajuddin Shaikh
Authorised Signatory

Date: 15 December 2023
Place: Pune

